Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipelineDren Bio deep B-cell ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune syste ...

Paris, March 20, 2025. Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201 ...

Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201. The French healthcare group will acquire the Dren Bio ...

Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid ...

DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing promise in treating refractory B-cell-mediated autoimmune diseases.

Sanofi (SNY) and Dren Bio, a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has ...

Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with a promising bispecific antibody.

Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company ...

Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio Inc. for $600 million upfront ...